Research news Mouse experiments have suggested that glucagon-like peptide-1 receptor agonists may reduce pulmonary fibrosis following a COVID-19 infection in people with type 2 diabetes, although researchers cautioned that the findings remain preliminary Glucagon-like peptide-1 (GLP-1) receptor agonists, already used to treat type 2 diabetes (T2DM) and obesity, may also help to reduce the risk of COVID-19-related lung scarring in people with T2DM, according to research in mouse models
Additionally, the ethical landscape of off-label prescribing is continuously evolving, with new research findings emerging regularly
Or the people who stand to make millions if the answer is "yes"
For example, naltrexone is contraindicated for individuals who are currently taking opioid pain medications or those who have acute hepatitis or liver failure
Nature Reviews Molecular Cell Biology, 5 (9), 699711.
15 Phase II trials targeting MASH have shown that treatment with SEMA 0.4 mg daily for 72 weeks resulted in more patients with liver fibrosis stage F2/F3 achieving improvement in MASH without progression of liver fibrosis (odds ratio = 6.87, 95% CI = 2.6017.63) compared to placebo
